

**Ref. No.:** EIKO/BSE/2024-25/60

**Date:** 14<sup>th</sup> February, 2025.

To,  
Corporate Services Department,  
**BSE Limited**,  
Phiroze Jeejeebhoy Towers,  
1st Floor, Dalal Street,  
Fort, Mumbai - 400001.

**Scrip Code:** 540204

**Subject:** Newspaper Publication.

Dear Sir/ Madam,

Pursuant to Regulations 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed a copy of newspaper publication in the following newspapers with respect to Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2024 approved at the meeting of Board of Directors held on Wednesday, 12<sup>th</sup> February, 2025.

1. Financial Express (English)
2. Mumbai Lakshadweep (Marathi)

Copy of the results are also uploaded on the website of our Company - [www.eikolifesciences.com](http://www.eikolifesciences.com).

Kindly take the same on your records.

Thanking you,  
Yours sincerely.

**For Eiko Lifesciences Limited**

**Chintan Doshi**  
**Compliance officer & Company Secretary**  
**Membership No: A36190**  
**Encl: Same as above**



Regd off: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagle Estate, Thane West MH 400604

**EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31-12-2024**

(₹ in Lakhs except EPS)

Sr. No.	Particulars	Standalone					Consolidated			
		Quarter Ended		Nine Months Ended		Year Ended	Quarter Ended		Nine Months Ended	
		31/12/2024 (Unaudited)	30/9/2024 (Unaudited)	31/12/2023 (Unaudited)	31/12/2024 (Unaudited)	31/12/2023 (Unaudited)	31/3/2024 (Audited)	31/12/2024 (Unaudited)	30/9/2024 (Unaudited)	31/12/2024 (Unaudited)
1	Total Income from Operations	701.54	786.98	662.53	2,589.79	1,960.11	2,810.54	758.15	828.58	2,687.99
2	Net profit/ (Loss) for the period before tax (before Exceptional and/ or extraordinary items)	38.08	28.03	29.10	112.23	56.13	98.42	54.12	35.26	135.50
3	Net profit/ (Loss) for the period before tax (After Exceptional and/ or extraordinary items)	38.08	28.03	29.10	112.23	56.13	98.42	54.12	35.26	135.50
4	Net profit/ (Loss) for the period after tax (After Exceptional and/ or extraordinary items)	28.49	20.81	23.76	83.98	43.85	75.15	39.73	25.78	100.20
5	Net profit after taxes and share of profit of Associates	28.49	20.81	23.76	83.98	43.85	75.15	42.21	28.15	107.50
6	Total comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax), share of profit of Associates and Other Comprehensive Income (after tax)]	28.49	20.81	23.76	83.98	43.85	77.55	42.21	28.15	107.50
7	Paid up equity share Capital	1,287.28	1,287.28	997.95	1,287.28	997.95	1,287.28	1,287.28	1,287.28	1,287.28
8	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year.	-	-	-	-	-	3,780.54	-	-	-
9	Basic Earning Per Share (Not Annualised) (EPS in ₹)	0.24	0.16	0.24	0.86	0.45	0.73	0.32	0.22	0.82
9	Diluted Earning Per Share (Not Annualised) (EPS in ₹)	0.24	0.16	0.24	0.86	0.45	0.73	0.32	0.22	0.82

**Note**

1 The above unaudited Standalone and Consolidated financial results for the quarter and nine months ended 31st December, 2024 was reviewed by the audit committee of the board on 12th February, 2025 and thereafter approved by the board of directors of the company at their meeting held on 12th February, 2025. Their Limited Review Report has no qualification / modification.

2 These financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended)

3 The above is an extract of the details format of Quarter and Nine Months Ended Results filed with the stock exchange under Regulation 33 of SEBI (listing Obligations and Disclosure Requirements) Regulation, 2015. The full format of the Quarter and Nine Months ended Financial Results are available on stock exchange website at www.bseindia.com and also on the company's website i.e., www.eikolifesciences.com

4 During the period, the company successfully acquired a 25.01% equity stake in Reflux Pharmaceuticals Private Limited ("RPPL"), thereby making it an associate company of Eiko LifeSciences Limited.

**Consolidated financial Results include financial results of:**

- a) Eiko Scientific Solutions LLP- Wholly Owned Subsidiary  
b) Eikovivify Logistics Private Limited- Subsidiary  
c) Reflux Pharmaceuticals Private Limited- Associate Company

Consequently, consolidated financial results have been prepared and presented for the current financial year. Since this is the first year in which the consolidated financial results are being reported, consolidated figures for previous financial year are not available.

For Eiko Lifesciences Limited

Sd/-

Chintan Doshi

Company Secretary & Compliance Officer

financialexp.epapr.in

A36190

Date: 12-02-2025

Place: Thane

